Animal models for aberrations of gonadotropin action

Hellevi Peltoketo · Fu-Ping Zhang · Susana B. Rulli

Abstract During the last two decades a large number of genetically modified mouse lines with altered gonadotropin action have been generated. These mouse lines fall into three categories: the lack-of-function mice, gain-of-function mice, and the mice generated by breeding the abovementioned lines with other disease model lines. The mouse strains lacking gonadotropin action have elucidated the necessity of the pituitary hormones in pubertal development and function of gonads, and revealed the processes from the original genetic defect to the pathological phenotype such as hypo- or hypergonadotropic hypogonadism. Conversely, the strains of the second group depict consequences of chronic gonadotropin action. The lines vary from those expressing constitutively active receptors and those secreting follicle-stimulating hormone (FSH) with slowly increasing amounts to those producing human choriogonadotropin (hCG), amount of which corresponds to 2000-fold luteinizing hormone (LH)/hCG biological activity. Accordingly, the phenotypes diverge from mild anomalies and enhanced fertility to disrupted gametogenesis, but eventually chronic, enhanced and non-pulsatile action of both FSH and LH leads to female and male infertility and/or hyper- and neoplasias in most of the gonadotropin gain-of-function mice. Elevated gonadotropin levels also alter the function of several extra-gonadal tissues either directly or indirectly via increased sex steroid production. These effects include promotion of tumorigenesis in tissues such as the pituitary, mammary and adrenal glands. Finally, the cross-breedings of the current mouse strains with other disease models are likely to uncover the contribution of gonadotropins in novel biological systems, as exemplified by the recent crossbreed of LHCG receptor deficient mice with Alzheimer disease mice.

Keywords Gonadotropin · Receptor · Ovary · Testis · Pituitary · Genetically modified

1 Introduction

Since the close connection between pituitary and gonads was revealed, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and their receptors have been intensively studied with the aim of understanding the function and malfunction of these organs. In this current review we concentrate on the experimental animal models that have elucidated the role of gonadotropins in normal gonadal function and, more importantly, what aberrations are caused by their abnormal actions in gonads and extra-gonadal tissues. Numerous mouse models with disrupted or enhanced gonadotropin signalling have been generated (Table 1). The phenotypes of these mice mimic several human conditions such as hypo- or hypergonadotropic hypogonadism, premature ovarian failure and ovarian hyperstimulation syndrome. The mouse strains and their crosses with other disease model lines are also useful when testing other hypotheses, such as gonadotropin action in tumorigenesis, bone metabolism and Alzheimer disease.
Table 1 Mouse lines with disrupted or enhanced gonadotropin production and loss- and gain-of-function mutations of gonadotropins and their receptor

A. Mouse lines with disrupted gonadotropin production

| Mouse line | Gene modification | References |
|------------|-------------------|------------|
| Kiss1−/−   | Deletion of the exons 1 and 2 | [79] |
| Gpr54−/−   | Disruption of the first and second exon; disruption of the second exon | [80, 81] |
| hpg        | Spontaneous mutation; deletion of the exons 3 and 4 of Gnrh | [82] |
| GnrhrA117P | ENU-induced mutation | [83] |
| Gnrhr−/−   | Gene trap insertion to disrupt the exons 2 and 3 | [84] |

B. Mouse lines with loss-of-function modification in a gonadotropin or its receptor

| Mouse line | Gene modification | References |
|------------|-------------------|------------|
| hpg        | Spontaneous mutation; deletion of the exons 3 and 4 of Gnrh | [82] |
| Fshβ−/−    | Deletion of the exons 1-3 | [1] |
| Fshr−/−, Forko | Deletion of the exon 1 | [2, 3] |
| Lhβ−/−     | Disruption of the second exon | [4] |
| Lhcgr−/−, Lurko | Deletion of the exon 11; deletion of the exon1 | [5, 6] |

C. Mouse lines with enhanced gonadotropin action

| Mouse line | Promoter(s) | Gene modification | References |
|------------|-------------|-------------------|------------|
| Lh3CTP+b   | bCGA       | Transgenic line expressing the fusion gene of bLHB and CGB | [31] |
| Lh3CTP+bTag| bCGA and Inha | Double transgenic line expressing the fusion gene of bLHB and CGB and SV40 Tag | [38] |
| UBC-hCGβ+b | UBC       | Transgenic line expressing CGB | [33] |
| Mt1-hCGβ+b | Mt1      | Transgenic line expressing CGB | [30] |
| UBC-hCGα+b | UBC       | Double transgenic line expressing CAG and CGB | [44] |
| Mt1-hCGα+b | Mt1      | Double transgenic line expressing CAG and CGB | [30] |
| YHR+       | Inha     | Transgenic line expressing the fusion gene of CAG, CGB and rLhcgr | [32] |
| rLHRD556+, | Inha     | Transgenic line expressing CAM rLhcgrD556 | [32] |
| Mt1-hFSHα+b | Mt1    | Double transgenic line expressing CAG and FSHB | [24] |
| Ins2-hFSH−b| rIns2   | Double transgenic line expressing CAG and FSHB | [22] |
| Ins2−hFSH−+ | rIns2 | Double transgenic line expressing CAG and FSHB | [85] |
| FSHR−D556G+ | rAbp     | Transgenic line expressing CAM FSHRD556G in hpg background | [86, 87] |
| FSHR+xhpg  | rAbp     | Transgenic line expressing FSHR in hpg background | [87] |
| FshrD580Y+ | AMH      | Transgenic line expressing CAM FshrD580Y | [18] |
| FshrD580H+ | AMH      | Transgenic line expressing CAM FshrD580H | [18] |
| Fshr−D580Y−ki | endogenous Fshr | Knock-in line expressing CAM FshrD580Y | [18] |

ENU N-ethyl-N-nitrosurea

b bovine; h human; m mouse; r rat; ABP androgen binding protein; AMH anti-Mullerian hormone; CAG glycoprotein hormone—alpha polypeptide (α-subunit); CGB beta; FSHβ follicle stimulating hormone beta; Fshr follicle stimulating hormone; Gnrhr gonadotropin releasing hormone receptor; Gpr G protein-coupled receptor; hpg hypogonadal; Ins insulin; Kiss kiss-metastasis suppressor; LHB luteinizing hormone beta; Lhcgr luteinizing hormone/choriogonadotropin hormone receptor; Mt1 metallothionein; SV40 Simian virus 40; Tag T-antigen; Ub ubiquitin; CAM constitutively active mutant

* Depicts expression of a transgene in addition to endogenous genes

The focus of the review being in the aberrations of gonadotropin action, the mice of the section A have been listed to demonstrate upstream events of the gonadotropin biosynthesis, but they have not been discussed except hpg mice

When two different mouse strains expressing the same gene but under different promoter have been generated, abbreviation of a promoter has been included into the strain name

2 Experimental animal models for gonadotropin action in ovary

The main target of gonadotropins in females is the ovary, maturation of which is triggered by LH and FSH at puberty. It is largely agreed and confirmed by animal models lacking FSH, LH or their receptors that the gonadotropins are not critical for the prenatal female uro-genital development. Nevertheless, loss-of-function mutations in any of the gonadotropins or their receptors lead to delayed or interrupted progression of puberty, hypogonadism, primary amenorrhea, and consequently infertility [1–6]. In the absence of FSH or LH signalling, ovarian follicle growth does not progress beyond the preantral or early antral stage, respectively, leading to a deficit in estrogen and progesterone production and anovulation both in humans and...
rodents. Mice lacking gonadotropin function and their consistency with corresponding human ovarian conditions have been discussed in detail in several excellent review articles elsewhere [7–10]. Therefore we concentrate here in more detail on the role of gonadotropins in folliculogenesis, ovarian tumorigenesis and on the consequences of excess gonadotropin signalling, as demonstrated by the genetically manipulated animal models.

2.1 Role of gonadotropins in the formation and maintenance of the primordial follicle pool

The gonadotropin-dependence of ovarian function begins at puberty and involves the advanced follicular stages, but gonadotropins—and FSH in particular—may also affect the earlier stages starting the neonatal primordial folliculogenesis. FSH receptor (Fshr) is expressed in the neonatal mouse ovary and its expression increases significantly within the first three postnatal days together with serum FSH. In vitro FSH promotes mouse oocyte survival during the initial follicle formation by decreasing the apoptosis of the oocytes and by timing germline nest breakdown [11]. Similarly, the serum FSH peak coincides with the time of nest breakdown in developing human ovaries [12]. The early involvement of FSH in initial folliculogenesis is further emphasised by the data showing that anti-FSH treatment of hamster dams during pregnancy leads to reduced number of primordial follicles in pups [13] and that the amount of naked oocytes is substantially reduced in 2-day-old FSHR-deficient Forko mice. [14]. In addition, there are more growing, i.e. primary and secondary follicles in the newborn Forko mice than in wild-type animals, indicating disturbances in the timing of the initial follicular recruitment in the absence of FSH signalling.

In pubertal Forko females, the loss of primordial follicles is not accelerated compared to wild-type mice, suggesting that FSH action is not needed to maintain the primordial follicle pool. Conversely, FSH signalling linked to anti-Müllerian hormone (AMH) action may be involved in removing the excess of primordial follicles after the initial formation of the pool [14, 15]. In pubertal Forko [14] and adult hypogonadal (hpg) [16] mice that are lacking both LH and FSH, the number of primordial follicles is higher than in age-matched wild-type mice, and gonadotropin treatment of the hpg females causes an accelerated decrease of the follicular pool. In agreement, chronically elevated LH [17] and the constitutively active form of mFSHR, mFSHR-D580H [18], lead to substantially accelerated loss of primordial follicles in the adult mice. Atresia of primordial follicles is apparently increased in the presence of excess gonadotropin action, since their augmented recruitment into the growing pool has not been detected [17, 18]. Since the gonadotropin receptors are absent in primordial follicles [19–21], the larger gonadotropin-responsive follicles may secrete a factor/factors promoting apoptosis of primordial follicles or inactivate any other/s supporting their survival.

2.2 Aberrant gonadotropin action during the gonadotropin-responsive, but not -dependent phase of follicular growth in mature mice

During follicular growth the earliest signs of FSHR and Fshr expression have been detected in the cuboidal granulosa cells of the primary follicles with a subsequent increase in more advanced follicles [19, 20]. The expression of ligand-responsive luteinizing/choriogonadotropin receptor (LHCGR) begins in the forming theca cell layer [21]. During this gonadotropin-responsive, but not yet dependent phase, the lack of gonadotropin signalling results in decreased number of secondary follicles [14, 16], but more importantly, they are susceptible to the excess of gonadotropin action, for instance caused by gain-of-function mutations in their receptors or exogenous gonadotropin production by endocrine tumors. Both chronically elevated LH [17] and FSH [22] as well as action of the constitutively active FSHR-D580H [18] lead to accelerated loss of small growing follicles and to abnormalities in the remaining follicles. The low number of the small growing follicles may thus be caused by the earlier described exhaustion of the resting follicle reserve and consequently decreased number of the recruited follicles. The enhanced gonadotropin action can also accelerate the growth of the remaining recruited follicles as it happens in mice expressing FSHR-D580H, Fshr<sup>D580H+</sup> mice [18].

The collective data from the animal models suggest that during the early steps of folliculogenesis FSH is involved in the timing of the germline nest breakdown, protecting the perinatal primordial pool, and initiating the follicle recruitment (Table 2). Later on the protective role of FSH for the primordial pool is lost and conversely, the excess of FSH and LH indirectly accelerates the loss of primordial follicles. Both absent and increased FSH and LH action results in a reduced number of small growing follicles, and the augmented gonadotropin action leads to defects in the remaining follicles (see below). Therefore unbalanced gonadotropin signalling may be a factor leading to premature ovarian failure in women.

2.3 Aberrant gonadotropin action during the gonadotropin-dependent phase of follicular growth

In the absence of FSH and LH action, ovarian follicles develop until the preantral and early antral stage, respectively [1–6] (Table 2), thus verifying the need for gonadotropins in cyclic recruitment and pre-ovulatory growth of follicles, but not for the initial formation of...
granulosa or thecal cell layers. Arrest of follicle development results in small ovarian size, decreased production of inhibins [3] and estradiol [4–6, 23] as well as missing ovulation and luteinisation, leading to decreased progesterone production [1, 4–6, 23]. The insufficient production of ovarian hormones causes uterine atrophy and disordered estrous cycles, and the concomitant lack of negative feedback from ovary to hypothalamic-pituitary axis results in chronic secretion of both FSH and LH, when either of the gonadotropin receptor is missing [1–6]. Increased and non-pulsatile secretion of one gonadotropin, however, cannot compensate for the lack of the other.

Chronically increased FSH action causes serious abnormalities in ovarian function that correlates to the level of the excess of FSH signalling. The Ins2-hFSH+ line represents the situation, in which the serum concentration of FSH gradually rises during the aging of the mice. The augmented FSH levels in Ins2-hFSH+ mice exert a biphasic effect on fecundity, first seen as increased litter size but later as premature infertility [22]. Similarly, young Fshr<sup>D580H+</sup> mice expressing a modest level of constitutively active receptor show increased fertility, but with aging or upon further increased expression of Fshr<sup>D580H+</sup> their fertility is severely compromised [18]. Expression of Cyp19 is increased in the Fshr<sup>D580H+</sup> ovaries causing increased estradiol production and consequently high prolactin secretion. These apparent changes cause perturbation of the LH surge leading to appearance of luteinized—but unruptured follicles (Fig. 1a–b). In addition, the hormonal imbalance disrupts the estrous cycle, and alters the vaginal epithelium and its capacity to support implantation. Also other structural alterations are common in the Fshr<sup>D580H+</sup> ovaries; at the age of 2 to 3 months they are hyperstimulated, but contain numerous hemorrhagic follicles of poor quality (Fig. 1a–b); periodic acid Schiff—positive cell clusters with foamy and multinuclear cells are evident in ageing mice (Fig. 1c–f); and in the most affected animals the surface epithelium is hyperplastic [18]. In addition, germ-cell tumors, teratomas, are apparent in a fraction of the Fshr<sup>D580H+</sup> ovaries [18]. Finally, the supra-physiological amount of circulating FSH in Mt1-<i>FSH</i>+ mice leads to quick deterioration of follicle function and infertility [24]. Folliculogenesis initiates normally in these mice, but by 6–7 weeks of age the ovaries are packed with massive fluid-filled and hemorrhagic cysts, and in 8-month old mice no late-stage follicles or corpora lutea are seen any more [24].

FSH acts as a determining factor in the cyclic recruitment of follicles and as a survival factor for antral follicles to rescue them from atresia [25]. The current mouse strains show that excess FSH action can also overrule quantity and quality control mechanisms in selection of dominant follicles such as those regulated by AMH [26]. FSH regulates the proliferation of granulosa cells in the growing follicles, which function is reflected by decreased cyclin D2 expression in Forko mice [14] and increased Ki67 expression in Fshr<sup>D580H+</sup> mice [18]. A notably higher number of primary and secondary follicles are Ki67-positive in Fshr<sup>D580H+</sup> than in wild-type mice, thus apparently leading to the accelerated growth of the follicles and explaining the ovarian hyperstimulation detected in young adult Fshr<sup>D580H+</sup> females (Fig. 1a–b). These mice have an increased number of large growing follicles, several of them being hemorrhagic, and the progression into large follicles continues even though the ovaries show premature ageing and accelerated loss of small follicles (Fig. 1c–e) [18]. In agreement, the amount of corpora lutea and uterine implantation are significantly higher in young <i>Ins2-hFSH</i>+ than wild-type females leading to larger litters [22].

---

**Table 2** Influence of the aberrant gonadotropin action on the folliculogenesis. In each case the condition has been compared with the situation in a wild type mouse.

| Amount of naked oocytes; initial primordial folliculogenesis | Loss of FSH action | Increased FSH action | Loss of LH action | Increased LH/hCG action | References |
|------------------------------------------------------------|--------------------|----------------------|------------------|--------------------------|------------|
| Postnatal mouse                                            | Decreased          | Increased            | dna              | dna                       | [11, 14]   |
| Peripubertal and adult mouse                                | Increased          | dna                  | dna              | dna                       | [14]       |
| The initial recruitment                                     | Increased          | Increased            | dna              | dna                       | [11, 14]   |
| Peripubertal and adult mouse                                | Increased          | Increased            | dna              | dna                       | [14]       |
| The pool of primordial follicles (primary to preantral)     | Larger             | Decreased            | Larger           | Decreased                 | [14, 16–18]|
| Number of small follicles                                   | Decreased          | Decreased            | dna              | Decreased                 | [14, 16–18]|
| Only early antral follicles                                 | Increased in young mature animals | Only early antral follicles | No effect | [1–6, 17, 18] |
| Presence of hemorrhagic follicles                           | Not reported        | Yes                  | Not reported     | Yes                       | [18, 24, 30–32]|

*dna* data not available
In mice, as females become older their litter sizes decrease due to increased reabsorption of embryos, also implying poor quality of ovulated and fertilized oocytes. It is generally understood that the leading follicles grow faster than the rest of the cohort producing higher amounts of estradiol and inhibins than the others [25]. Ins2-hFSH+ and FshrD580H+ females, however, escape the negative feedback of estrogens and inhibins and its influence on FSH secretion, and thus also the remaining antral follicles besides the leading ones continue to grow, bringing about the phenotype of hyperstimulated ovaries. It mimics the ethiology of the human pregnancy-dependent ovarian hyperstimulation syndrome that is caused by activation of a mutated ligand-nonspecific FSHR by hCG [27].

While FSH signalling is critical for the follicular development from preantral to early antral phase, LH signalling is essential for the further steps to pre-ovulatory stage and ovulation, and it cannot be compensated for by high-dose FSH [28]. The under-development of the reproductive organs and female infertility are due to low estrogen production and anovulation in Lhcr deficient Lurko mice. Accordingly they demonstrate a dramatic decrease in the ovarian mRNAs for steroidalogen proteins, steroidalogen acute regulatory protein (StAR), cytochrome P450-side-chain cleavage (P450-ssc), and P450-aromatase with being practically undetectable [6, 28]. Lurko mice also lack the LH stimulus that is needed to express sufficiently and temporally several genes associated with ovulation, such as Pr, Cox-2, Tsg-6, amphiregulin, epiregulin and β-cellulin [28]. Whereas high doses of FSH can induce ovulation in hypophysectomised rodents [29], this does not occur in Lurko mice indicating that Lhcr expression, by unknown mechanism, may be needed for the FSH-induced ovulation. Whether LHCR/FSHR dimerisation is necessary for this event remains to be evaluated.

Excessive LH signalling also leads to female infertility due to abnormal follicle maturation and lack of ovulation. Depending on amount of excessive gonadotropin stimulation, transgenic female mice develop progressively failing ovaries. The young low-copy Mt1-hCG+ females produce offspring similar to wild-type mice, but the former become infertile by 6–7 months for unknown reasons [30]. Folliculogenesis in high-copy Mt1-hCG+ females, instead, disrupts before ovulation and the ovaries turn largely hemorrhagic and cystic, the mice thus being infertile through their life. In young LhβCTP+ [31], YHR+ [32], and UBC-hCGβ+ [33] mice (for details see Table 1), folliculogenesis progresses until luteinization, but due to...
constant LH/hCG stimulus rather than a gonadotropin surge, oocytes are found trapped inside luteinized follicles and mice are infertile. At the age of 1 month estradiol production is increased in \( UBC\cdot hCG^{α/β} \) mice [33], but as the females ages, intensive luteinization takes place (Fig. 1f), and the elevated estradiol concentration is replaced by high progesterone and testosterone secretion [33]. In \( LHβ\cdot CTP^{+} \) [31] and \( YHR^{+} \) [32] females estradiol production remains elevated aside increased progesterone production, leading to hypertrophic uterine growth. Moreover, very high hCG production—comparable to 2000-fold biological LH/CGR activity—in \( UBC\cdot hCG^{+} \) females causes formation of bilateral teratomas.

In \( LHβ\cdot CTP \) and \( YHR^{+} \) strains LH signalling is prematurely initiated, and evident precocious puberty occurs in female mice reflected by early vaginal opening, advanced follicle growth and an enlarged uterus [32, 34]. The results imply that prepubertally excessive LH action is able to trigger increased estradiol production despite reduced FSH concentration. While the different gonadotropin-related mouse models in general are good phenocopies for several human disorders, in case of gonadotropin-related precocious puberty there are distinct dissimilarities between the species. Women carrying the same gain-of-mutations in \( LHCGR \) that causes testotoxicosis in their male relatives do not suffer from any obvious endocrine problems such as premature puberty, hyperandrogenism or infertility, contrasting the \( LHβ\cdot CTP^{+} \) females estradiol secretion at the normal age of puberty.

The role of FSH in promoting somatic cell tumors is more complicated. Firstly, most \( Forko \) mice older than a year develop both sex-cord and epithelial ovarian tumors including granulosa cell tumors and serous papillary epithelial adenomas [39, 40]. Aging \( Fshr^{D580H}^{+} \) mice also develop ovarian surface epithelial hyperplasia [18] and the presence of FSH accelerates the formation of granulosa cell tumors in inhibin-α-deficient mice [24] suggesting, that FSH signalling can both suppress and support hyper- and metaplastic growth of several cell types directly or indirectly. Interestingly, according to a recent finding the expression of \( FSHR \) is promoted in endothelial cells at the borderline area of different kinds of human malignant tumors [41] prompting the question about a possible role of FSH in the progression and invasion of cancer in general.

### 3 Experimental animal models for gonadotropin action in testis and male accessory glands

Similarly to ovarian function in women the gonadotropins, particularly LH, play a key role in the differentiation and maturation of testis in men. Mutations in \( LHβ \) and \( LHCGR \) causes various types of pathological conditions in men including lack of or delayed puberty, absence of secondary sexual characteristics and arrested spermatogenesis, while \( FSHβ \) and \( FSHR \) mutations lead to impaired testicular function but not necessarily to infertility [7]. During the last 15 years several genetically modified animal models for aberrant gonadotropin action have been generated and they have greatly increased knowledge of the molecular pathogenesis of gonadotropin-related conditions.

### 2.4 Potential role of gonadotropins in ovarian tumorigenesis

The potential role of gonadotropins in initiation and/or progression of ovarian tumors has been discussed for decades (for a recent review see [35], for example). Intriguingly, in genetically modified animals both excess and lack of gonadotropin action have been linked with tumorigenesis including germ cell, sex-cord and surface epithelial tumors. Firstly, strong stimulation of LH signaling causes development of mature teratomas bilaterally in all \( UBC\cdot hCG^{+} \) females [36], while unilateral teratomas have been detected in about 20% of \( Fshr^{D580H} \) female mice, with some of the tumors being immature [18]. High gonadotropin stimulation—both FSH and LH—of granulosa cells may thus interfere with oocyte maturation and trigger pathogenic activation of oocytes. Secondly, \( LHβ\cdot CTP^{+} \) females develop granulosa and theca cell tumors with ageing, but only in a genetically predisposed background and when the LH surge is not taking place [31, 34, 37]. Together with the finding that such tumors do not develop in \( UBC\cdot hCG^{+} \) mice [36], it suggests that excessive stimulation of LHCGR may be a promoting rather than an initiating factor in this response. Constant expression of \( LHβ\cdot CTP \) also accelerates development of the SV40 T-antigen-initiated granulosa cell tumors [38] further implying a role for LH/hCG in ovarian sex-cord cell tumorigenesis.
3.1 Aberrations in testis and male accessory glands of LHβ and LHCGR deficient mice

As with in females, LH action in males is essentially needed first time during the pubertal development. The testes of newborn LHCGR deficient, *Lurko* males are similar in size and microscopic appearance to those of wild type litters, and their intra-abdominal location adjacent to the urinary bladder is unchanged [5], indicating that LH signalling is not needed for prenatal testicular development. Adult LHβ deficient, *Lhβ−/−* and *Lurko* males instead are infertile, with their testis weight being about 25% of that in wild-type age-matched litters [4–6]. The accessory glands are also undersized consistent with decreased circulating (<10%) and intra-testicular (<5%) testosterone levels. Testicular histological analysis shows spermatogenesis, which is blocked at the round spermatid stage [5, 6], and insignificant interstitium with very few, small-sized Leydig cells [4–6]. Gene expression analyses have confirmed an increase in the fetal Leydig cell marker, thrombospondin-2, and reduction in many of the steroidogenic pathway enzymes. In addition, levels of the androgen precursor, androstenedione, are enhanced, indicating the presence of mostly fetal and immature Leydig cells in the *Lhβ−/−* testes [4].

Testosterone replacement therapy of *Lurko* males can partially restore the phenotypes and improve spermatogenesis beyond the round spermatid stage, but the mice remain sub-fertile. Fewer than 10% of all breedings have resulted in pregnancy, and only two of 13 mice (15%) tested have been fertile. The reasons for this include poor accessory sex gland function and impaired sexual behaviour, as well as inflammation in the epididymis and prostate in many testosterone-treated *Lurko* mice [42]. Surprisingly, by the age of 12 months the arrested spermatogenesis in untreated *Lurko* testes has appeared to be progressed further, until elongated spermatids at late stages 13–16, indicating that spermatogenesis can be completed even without LH signalling and high intratesticular testosterone concentration (Fig. 2). Late-onset recovery of spermatogenesis in *Lurko* mice suggests that only total abolition of testicular androgen action may result in consistent azoospermia necessary for effective male contraception [5].

Recently, transgenic mice co-expressing binding-deficient and signalling-deficient forms of LHCGR in

---

**Fig. 2** Representative light micrographs of testicular sections from homozygous *Lurko* (−/−) and wild type control (+/+), 12 mo mice. Samples were taken from *Lurko* (−/−) at the ages of 2 months (a and b) and 12 months (c and d) and from control wild-type mice at 12 months (e and f). b, d, and f are views of a, c, and e at higher magnification. Arrows and arrowheads indicate round spermatids and elongated spermatids, respectively. *mo* month. The figure is a modification from the original figure presented in [78].
...sperm is normal. Similarly, the subunit C type mice, spermatogenesis is completed and quality of 
[32, 44]. Though the mice have smaller testes than wild-type males, their moderate increase in bioactive hCG and LH signalling 
activates the biological activity of hCG. In contrast, the double transgenic UBC-hCG+ and YHR+ males are fertile and show only mild anomalies, in agreement with their moderate increase in bioactive hCG and LH signalling 
[32, 44]. Though the mice have smaller testes than wild-type mice, spermatogenesis is completed and quality of sperm is normal. Similarly, the subunit Cα overproducing males demonstrate no obvious abnormalities, in keeping with the necessity of α/β dimerization for the biological activity of hCG. In contrast, the double transgenic UBC-

3.2 Aberrations in male LH/hCG/YHR over-expressing mice

Several experimental animal models demonstrate the influence of enhanced LH signalling on the function of testis; the stronger the LH signalling is, the more severe the consequences are. UBC-hCG/β and YHR+ males are fertile and show only mild anomalies, in agreement with their moderate increase in bioactive hCG and LH signalling 
[32, 44]. Though the mice have smaller testes than wild-type mice, spermatogenesis is completed and quality of sperm is normal. Similarly, the subunit Cα overproducing males demonstrate no obvious abnormalities, in keeping with the necessity of α/β dimerization for the biological activity of hCG. In contrast, the double transgenic UBC-

3.3 Aberrations in testis and male accessory glands in FSHβ and FSHR deficient mice

FSH signalling is not as crucial for testicular function as LH is. Both FSHβ and FSHR deficient (Fshβ/−/− and Forko) mice are fertile despite the reduced testis size and seminiferous tubule volume [1–3]. Stereological analyses have confirmed around 30% reduction in Sertoli cell number and germ cell carrying capacity, consistent with reduced testis size in Fshβ/−/− mice [46, 47]. The number of Leydig cells and concentration of intratesticular testosterone increase slowly in Forko mice after puberty and are significantly reduced in adult animals [48]. This is associated with reduced levels of mRNA encoding P450-scc, 3β-hydroxysteroid dehydrogenase type VI, and StAR in Forko mice [48]. The accessory glands of the Fshβ/−/− mice are however normal, verifying the presence of adequate number of Leydig cells and serum testosterone concentration [1].

Spermatogenesis is completed and many tubules contain mature spermatozoa in Fshβ/−/− and Forko testes though partial spermatogenic failure has been observed [1–3]. Flow cytometric evaluation of germ cells has revealed a significant increase in the percentage of spermatogonia and non-germ cells in Forko mice, with substantially less elongated spermatids than their wild-type littermates. Defects in sperm head shape, chromatin condensation, and chromatim remodelling are also apparent [49, 50], thus leading to decreased sperm viability and motility, and consequently reduced fertility and a delay in the first mating [49].

3.4 Aberrations in male FSH over-expressing mice

Overexpression of FSH, such as in Mt1-fSH+ mice, results in normal testicular development and lack of any obvious histological defects in adult testes [24]. The seminiferous tubules are healthy and intact, spermatozoa are abundant in the lumen, and the number of Leydig cells in the interstitial spaces is normal [24]. In addition, Mt1-FSH+ mice show enlarged seminal vesicles secondary to elevated serum testosterone levels. Nevertheless, the Mt1-FSH+ mice are infertile that is thus caused by behavioural rather than structural defects. In other mouse lines with enhanced FSH signalling, obvious perturbations in testicular function have not been reported.

Interestingly, the testes of Ins2-fSH+xhp mice (for details, see Table 1) are up to 5-fold larger than those of hpg only mice depending on FSH concentration. Only the Ins2-fSH+xhp mice having serum FSH level higher than 1 IU/liter show larger testes than hpg-only mice, indicating a physiological FSH threshold for the testicular response [51, 52]. Enlarged Ins2-fSH+xhp testes contain round
spermatids and a sparse number of elongated spermatids. Hence without LH-induced testosterone production, FSH action alone on Sertoli cells may facilitate the completion of meiosis and minimal initiation, but not completion of spermiogenesis. Furthermore, transgenic FSH expression in hpg mice restores the number of Sertoli cells to the same level as in mature wild-type mice in a dose-dependent fashion, despite the absence of LH and persistently low intratesticular testosterone [52]. Altogether, FSH alone can stimulate the complete development of Sertoli cells but spermatogenesis does not occur without LH signalling [52].

4 Consequences of excessive gonadotropin action on pituitary function

The aberrant action of gonadotropins leads to many endocrine disorders, both in humans and experimental animal models [7, 53]. The intensity and complexity of the pathology are affected by the amount of hormones produced, duration of the stimulus, and the period in which the hormone stimulus is active. Transgenic mice with overproduction of hCG/LH, such as LH/CTP+ hCGβ/β and UBC-hCG+ mice have revealed novel phenotypes in pituitary function, both in males and females [31, 33, 36, 44, 54–56]. Female mice bearing constitutively active mutations of the FSHR, FshrD580H+ mice, also demonstrate distinct alterations in their pituitary function [18]. However, in all of the mouse strains the pituitary disorders are apparently secondary to increased gonadal hormone production.

The UBC-hCGβ+ mice produce moderate amounts of hCGβ subunit in a large number of tissues [33, 44], and the transgenic hCGβ-subunit associates with the endogenously expressed common α-subunit to form bioactive hCG. The dimerization results in around 40-fold increase in LH/hCG bioactivity in females [33], but only 3- to 4-fold increase in males [44]. The amount of endogenous α-subunit limits the dimerization process of hCG that is obligatory for hormonal activity, the individual hCG subunits being devoid of bioactivity [57]. The difference between male and female hCG secretion may be due to differences in feedback regulation of the common α-subunit expression by gonadal hormones [58]. Accordingly, UBC-hCGβ+ females produce high amounts of estradiol, testosterone and progesterone from the early stages of sexual maturation [33].

One of the most intriguing phenotypes observed in the UBC-hCGβ+ mice is the presence of lactotrope hyperplasia followed by development of prolactinomas in adult female mice [33, 55]. This is strictly dependent on the ovarian function, since ovariectomy prevents the hyperprolactinemia and pituitary adenoma formation, despite persistently elevated serum hCG concentration. Similarly, the FshrD580H+ females exhibit increased serum concentration of estradiol and prolactin in association with adenomatous pituitary growth [18]. The constantly enhanced estradiol stimulation apparently causes the development of prolactinomas in FshrD580H+ females, whereas in UBC-hCGβ+ mice ovarian estradiol production is elevated only temporarily before puberty [44]. The well-known influence of estradiol in the induction of pituitary adenomas [59] is therefore insufficient to explain the tumor pathogenesis in the latter mice. Instead, ovarian progesterone production remains high in UBC-hCGβ+ females and in agreement with this, excess progesterone has been shown to promote the growth of primary mouse pituitary cells and rat somatolactotrope GH3 cells in the presence of physiological levels of estradiol [55]. Evidence for the involvement of progesterone is also obtained in vivo; antiprogestin mifepristone treatment inhibits pituitary tumor growth in UBC-hCGβ+ females, and combined estradiol/progesterone treatment is more effective than estrogen treatment alone in inducing tumor growth after gonadectomy. The molecular mechanism of progestin-induced growth of rodent pituitary cells involves the activation of the tumorigenic cyclin D1/cyclin-dependent kinase 4/retnoblastoma protein/transcription factor E2F1 signaling cascade [55], which has profound similarities with development of human pituitary adenomas [60]. The importance of these studies lies in the potential role of the hCG overproducing mouse model for addressing the development and treatment of pituitary adenomas in individuals with high gonadotropin levels (such as after menopause).

The double transgenic UBC-hCG+ mouse model that co-expresses both the common α- and hCGβ-subunit transgenes produces highly elevated levels of dimeric hCG, reaching as high as 2000-fold increase in LH/hCG biological activity [36, 44]. In UBC-hCG+ males the concentration of androgens is elevated from the early development and they induce a profound and persistent malfunction of the neuroendocrine feedback control [56]. This results in accelerated hypothalamic GnRH pulse release and concomitant suppression of the pituitary-gonadal axis, which can be re-established only by blocking the androgen action perinatally [56]. These findings suggest the existence of a critical window in perinatal life, when androgens determine the level of activation of the male hypothalamic-pituitary axis, and that high androgen concentration can persistently shut down the pituitary gonadotrope differentiation and gonadotropin synthesis and secretion. A direct testosterone-dependent stimulation of the hypothalamic aromatase expression has been demonstrated in UBC-hCG+ males, and hence hypothalamic aromatization of gonad-derived androgens to estradiol may play a key role. These findings strongly suggest that androgen excess is able to disrupt the developmental programming of the male hypothalamic-pituitary-gonadal axis in mice [56].
5 Impact of abnormal gonadotropin action on tissues outside the hypothalamic-pituitary-gonadal-axis

Gonadotropins, in particular LH, are suggested to exert their effect via receptor binding on several extra-gonadal tissues. In addition, imbalanced gonadal hormone production caused by disturbed gonadotropin action affects the function of several tissues outside the hypothalamic-pituitary-gonadal axis. The mammary gland is an obvious target for the enhanced disturbed gonadotropin action. Increased LH and FSH signalling may indeed cause hyperplastic or even malignant growth of the gland directly or due to the enhanced ovarian estradiol, prolactin and/or progesterone production. $Fshr^{D580H+}$ females display typical pseudopregnant appearance with augmented lobulo-alveolar growth, but malignant transformation has not been detected in this strain [18]. Mammary gland development is also accelerated in $LHβCTP+$ mice, with young virgin mice having glands typical of late pregnancy [61]. During chronic LH signalling, mammary gland hyperplasia advances spontaneously to tumors, mainly in the form of intraepithelial neoplasias. They can further progress to invasive carcinomas, if the mice are treated with the mammary gland carcinogen, 7,12-dimethylbenz(a)anthracene [37, 61]. The aging $UBC-hCGβ+$ females show mammary epithelial hyperplasia and cytoplasm vacuolization that advances to adenocarcinoma with papillary or non-differentiated pattern [33]. The tumors are estrogen and progesterone receptor-negative, but instead resemble those induced by activated wnt/β-catenin pathway. Accordingly, they show increased β-catenin stabilization via up-regulation of wnt5b and wnt7b that is independent of the changes in ovarian steroidogenesis [62]. The capability of LH/hCG to modulate directly the wnt/β-catenin pathway in mammary epithelial cells may explain the severity of the consequences of its chronic and elevated action compared to FSH, the receptor of which is not expressed in the mammary gland.

During a woman's reproductive years, FSH has well-established osteoprotective functions via enhanced estrogen production. In agreement with this, the ageing $Forko$ females have skeletal abnormalities including kyphosis [23]. Conversely, in the presence of estrogen, FSH has been indicated to decrease bone mass directly via FSHR in osteoclasts [63]. That is supported by some clinical studies [64] and increased bone mass and decreased osteoclastic resorption in haploinsufficient $FSHβ+/-$ mice in comparison to $FSHβ+/+$ mice [63]. The bone metabolism in $Ins2-hFSH+$ and $Ins2-hFSH+xhp+ $ mice however demonstrate that FSH has, at least in mice, primarily anabolic effect on bone and that this effect is ovary-dependent and does not involve direct FSH actions on bone, or LH signalling either [65].

Abnormal gonadotropin function can lead to two different types of aberrations in adrenal glands. Firstly, gonadectomy and the concomitant increase in LH trigger adrenal hyperplasia and tumorigenesis in certain inbred mouse strains [66]. This is followed by increased proliferation of non-steroidogenic small spindle-shaped 'A cells' in the subcapsular adrenal cortex, and later on, by appearance of LH-responsive steroidogenic B cells that together construct disorganized tumorigenic adrenocortical architecture [66]. Ectopic upregulation of adrenal LHCGR, however, occurs in both tumorigenic and non-tumorigenic strains of mice, their F2 crossbreeds and their backcrosses, thus implying that adrenal LH action is not the immediate cause of tumors, but rather a promoting factor. A linkage analysis has revealed that post-gonadectomy adrenal tumorigenesis is driven by a quantitative trait locus on chromosome 18 and modulated by another one on chromosome 8, neither of them harbouring Lhcgr [66]. Other types of histological changes are observed in the adrenal gland of female $LHβCTP+$ [67], $UBC-hCGβ+$ [33] and $Fshr^{D580H+}$ [18] mice. At the cortico-medullary junction, a distinct layer of foamy and multinuclear cells is seen, which resembles the layer existing in estrogen-rich $UBC-Arom+$ male mice and the layer induced by chronic estrogen administration [68]. The estrogen-induced hyperplasia is accompanied by enhanced corticosterone synthesis and development of Cushing’s syndrome in the $LHβCTP+$ mice [67].

An interesting hypothesis is that LH can increase the susceptibility to Alzheimer disease (AD) [69]. Circumstantial evidence includes the presence of LHCGR in several brain regions [70, 71], the ability of LH and hCG to cross the blood-brain barrier [71], elevated LH concentrations in AD sufferers [72, 73], the linkage of certain LHCGR variants with reduced risk of AD [74], and the ability of LH to alter amyloid precursor processing toward the amyloidogenic pathway in vitro [75]. The cross-breeding of Lhgr knockout mice and APPsw− Alzheimer model mice expressing human amyloid precursor, convincingly support this hypothesis; in the absence of LH action, accumulation of amyloid-β peptide (Aβ) is reduced, astroglisis eases, and the production of several neuroproteins is corrected [76]. Elevated LH levels may hence promote Aβ accumulation and hasten AD progression and the cross-breeding of the two mouse strains may turn out to be useful when investigating AD pathogenesis. In addition, the abolition of FSH signalling leads to neurodegenerative changes due to the depletion of circulating estrogen. Forko females demonstrate several biochemical and morphological alterations in central and peripheral neurons [77].

6 Conclusions

Numerous abnormalities in the animal models with disrupted or enhanced gonadotropin action demonstrate the highly sensitive nature of the reproductive systems. Small changes in the circulatory gonadotropin concentration and timing of
gonadotropin action may alter the functions of gonads, the ovary in particular, and more drastic alterations like the complete abolition of gonadotropin action or chronic and intensely enhanced action, leads to sub- or infertility. In humans, deficiency of gonadotropins or their receptors results in hypogonadotropic and hypergonadotropic hypogonadism, respectively, while constitutively active gonadotropin receptors and gonadotropin-producing pituitary tumors can cause enhanced and chronic gonadotropin stimulus. Gonadotropin levels are also raised notably during pregnancy and postmenopausal years exposing women for enhanced gonadotropin stimulus. Thus mouse models are able to elucidate the mechanisms between the initial genetic defect and the eventual phenotype and may also predict possible outcomes of similar defects in humans paving the way for improved diagnostic and therapeutic strategies for these conditions.

For female fertility it is crucial to maintain the primordial follicular pool and ensure a proper follicular development and ovulation. The gain-of-function mouse lines demonstrate how a modest increase in FSH action can enhance fertility, but how more excessive and chronic gonadotropin action, of both FSH and LH, leads to accelerated loss of the primordial follicles, improper follicle development, enhanced ovarian hormone production, anovulation, and finally to disruption of the function of the hypothalamic-pituitary-gonadal axis. For males in turn it is fundamental to ensure proper development and function of the Leydig and Sertoli cells and to maintain undisturbed spermatogenesis, which functions are sensitive to lack of and excessive gonadotropin, mainly LH action.

The animal models have also proven valuable in the exploration of gonadotropin dependent biological systems outside of the gonads. They include developmental programing of the male hypothalamic-pituitary axis in mice and the linkage of the wnt/β-catenin and LH pathways in the development of mammary carcinomas. There is a strong correlation between the intensity of chronic gonadotropin signalling and severity of the outcome. Therefore a variety of models are needed to phenocopy and predict corresponding human syndromes. Although some of the mouse lines produce supra-physiological levels of gonadotropins, these may demonstrate the amplified effects of the consequences of long-lasting chronic gonadotropin stimulation.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Kumar TR, Wang Y, Lu N, Matzuk MM. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet. 1997;15(2):201–4. doi:10.1038/ng0297-201.
2. Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M, et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA. 1998;95(23):13612–7.
3. Abel MH, Wootton AN, Wilkins V, Huhtaniemi I, Knight PG, Charlton HM. The effect of a null mutation in the follicle-stimulating hormone receptor gene on mouse reproduction. Endocrinology. 2000;141(5):1795–803.
4. Ma X, Dong Y, Matzuk MM, Kumar TR. Targeted disruption of luteinizing hormone beta-subunit leads to hypothalamic defects, in gonadal steroidogenesis, and infertility. Proc Natl Acad Sci USA. 2004;101(49):17294–9. doi:10.1073/pnas.0404743101.
5. Zhang FP, Poutanen M, Wilbertz J, Huhtaniemi I. Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. Mol Endocrinol. 2001;15(1):172–83.
6. Lei ZM, Mishra S, Zou W, Xu B, Foltz M, Li X, et al. Targeted disruption of luteinizing hormone/human chorionic gonadotropin gonadotropin receptor gene. Mol Endocrinol. 2001;15(1):184–200.
7. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev. 2000;21(5):551–83.
8. Kumar TR. What have we learned about gonadotropin function from gonadotropin subunit and receptor knockout mice? Reproduction. 2005;130(3):293–302. doi:10.1530/repp.1.00660.
9. Tenasempere M. GPR54 and kisspeptin in reproduction. Hum Reprod Update. 2006;12(5):631–9. doi:10.1093/humupd/dml023.
10. Boulougand J, Ghervan C, Guiochon-Mantel A, Young J. Hypogonadotropic hypogonadism and GNRH1 mutations in mice and humans. Front Horm Res. 2010;39:11–20. doi:10.1159/000312697.
11. Lei L, Jin S, Mayo KE, Woodruff TK. The interactions between the stimulatory effect of follicle-stimulating hormone and the inhibitory effect of estrogen on mouse primordial folliculogenesis. Biol Reprod. 2010;82(1):13–22. doi:10.1095/biolreprod.109.077404.
12. Motta PM, Makabe S, Nottola SA. The ultrastructure of human reproduction. I. The natural history of the female germ cell: origin, migration and differentiation inside the developing ovary. Hum Reprod Update. 1997;3(3):281–95.
13. Roy SK, Albee L. Requirement for follicle-stimulating hormone action in the formation of primordial follicles during perinatal ovarian development in the hamster. Endocrinology. 2000;141(12):4449–56.
14. Balla A, Danilovich N, Yang Y, Sairam MR. Dynamics of ovarian development in the FORKO immature mouse: structural and functional implications for ovarian reserve. Biol Reprod. 2003;69(4):1281–93. doi:10.1095/biolreprod.103.015552.
15. Tingen C, Kim A, Woodruff TK. The primordial pool of follicles and nest breakdown in mammalian ovaries. Mol Hum Reprod. 2009;15(12):795–803. doi:10.1093/molehr/gap073.
16. Wang Y, Newton H, Spalviero JA, Allan CM, Marshan B, Handelsman DJ, et al. Gonadotropin control of inhibin secretion and the relationship to follicle type and number in the hpg mouse. Biol Reprod. 2005;73(4):610–8. doi:10.1095/biolreprod.105.039602.
17. Flaws JA, Abbud R, Mann RJ, Nilson JH, Hirshfeld AN. Chronically elevated luteinizing hormone depletes primordial follicles in the mouse ovary. Biol Reprod. 1997;57(5):1233–7.
18. Pelto-Keto H, Strauss L, Karjalainen R, Zhang M, Stamp GW, Segaloff DL, et al. Female mice expressing constitutively active mutants of FSH receptor present with a phenotype of premature follicle depletion and estrogen excess. Endocrinology. 2010;151(4):1872–83. doi:10.1210/en.2009-0966.
19. Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab. 1997;82(11):3748–51.
20. O’Shaughnessy PJ, Dudley K, Rajapaksha WR. Expression of follicle stimulating hormone-receptor mRNA during gonadal development. Mol Cell Endocrinol. 1996;125(1–2):169–75.

21. Gelety TJ, Magoffin DA. Ontogeny of steroidogenic enzyme gene expression in ovarian theca-interstitial cells in the rat: regulation by a paracrine theca-differentiating factor prior to achieving luteinizing hormone responsiveness. Biol Reprod. 1997;56(4):938–45.

22. McTavish KJ, Jimenez M, Walters KA, Spaliviero J, Groome NP, Themmen AP, et al. Rising follicle-stimulating hormone levels with age accelerate female reproductive failure. Endocrinology. 2007;148(9):4432–9.

23. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, Sairam MR. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology. 2000;141(11):4295–308.

24. Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC, et al. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol. 1999;13(6):851–65.

25. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000;21(2):200–14.

26. Visser JA, Themmen AP. Anti-Mullerian hormone and folliculo-stromal cell differentiation. J Endocrinol. 2004;181(1):151–63.

27. De Leener A, Montanelli L, Van Durme J, Chae H, Smits G, Van Royen K, et al. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Biol Reprod. 2000;62(5):1146–59.

28. Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH, et al. Elevated luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40-T-antigen fusion gene. Oncogene. 2003;22(21):3269–78.

29. Aravindakshan J, Chen XL, Sairam MR. Chronology and complexities of ovarian tumorigenesis in FORKO mice: age-dependent gene alterations and progressive dysregulation of Major Histocompatibility Complex (MHC) Class I and II profiles. Mol Cell Endocrinol. 2010;329(1–2):37–46. doi:10.1016/j.mce.2010.05.015.

30. Danilovich N, Roy I, Sairam MR. Ovarian pathology and high incidence of sex cord tumors in follitropin receptor knockout (FORKO) mice. Endocrinology. 2001;142(8):3673–84.

31. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363(17):1621–30. doi:10.1056/NEJMoa1001283.

32. Pakarainen T, Zhang FP, Maksela S, Poutanen M, Huhtaniemi I. Testosterone replacement therapy induces spermatogenesis and partially restores fertility in luteinizing hormone receptor knockout mice. Endocrinology. 2005;146(2):596–606.

33. Rivero-Muller A, Chou YY, Ji I, Lajic S, Hanyaloglu AC, Jonas K, et al. Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. Proc Natl Acad Sci USA. 2010;107(5):2319–24. doi:10.1073/pnas.0906695106.

34. Rulli SB, Ahtiainen P, Maksela S, Toppari J, Poutanen M, Huhtaniemi I. Elevated steroidogenesis, defective reproductive organs, and infertility in transgenic male mice overexpressing human chorionic gonadotropin. Endocrinology. 2003;144(11):4980–90. doi:10.1210/en.2003-0403.

35. Ahtiainen P, Rulli SB, Shariatmadari R, Pelleniemi LJ, Toppari J, Poutanen M, et al. Fetal but not adult Leydig cells are susceptible to adenoa formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice. Oncogene. 2005;24(49):7301–9.

36. Kumar TR, Varani S, Wreford NG, Teller NM, de Kretser DM, Matzuk MM. Male reproductive phenotypes in double mutant mice lacking both FSHbeta and activin receptor IA. Endocrinology. 2001;142(8):3512–8.

37. Wreford NG, Rajendra Kumar T, Matzuk MM, de Kretser DM. Analysis of the testicular phenotype of the follicle-stimulating hormone beta-subunit knockout and the activin type II receptor knockout mice by stereological analysis. Endocrinology. 2001;142(7):2916–20.

38. Baker PJ, Pakarinen P, Huhtaniemi IT, Abel MH, Charlton HM, Kumar TR, et al. Failure of normal Leydig cell development in follicle-stimulating hormone (FSH) receptor-deficient mice, but not FSHbeta-deficient mice: role for constitutive FSH receptor activity. Endocrinology. 2003;144(1):138–45.

39. Krishnamurthy H, Danilovich N, Morales CR, Sairam MR. Qualitative and quantitative decline in spermatogenesis of the follicle-stimulating hormone receptor knockout (FORKO) mouse. Biol Reprod. 2000;62(5):1146–59.

40. Xing W, Krishnamurthy H, Sairam MR. Role of follitropin receptor signaling in nuclear protein transitions and chromatin condensation during spermatogenesis. Biochem Biophys Res Commun. 2003;312(3):697–701. doi:10.1016/j.bbrc.2003.10.177.

41. Allain CM, Haywood M, Svaraj S, Spaliviero J, Koch A, Jimenez M, et al. A novel transgenic model to characterize the specific effects of follicle-stimulating hormone on gonadal physiology in the absence of luteinizing hormone actions. Endocrinology. 2001;142(6):2213–20.
52. Allan CM, Garcia A, Spaliviero J, Zhang FP, Jimenez M, Huhtaniemi I, et al. Complete Sertoli cell proliferation induced by follicle-stimulating hormone (FSH) independently of luteinizing hormone activity: evidence from genetic models of isolated FSH action. Endocrinology. 2004;145(4):1587–93.

53. Rulli SB, Huhtaniemi I. What have gonadotrophin overexpressing transgenic mice taught us about gonadal function? Reproduction. 2005;130(3):283–91.

54. Mohammad HP, Abbud RA, Parlow AF, Lewin JS, Nilson JH. Targeted overexpression of luteinizing hormone causes ovary-dependent functional adenomas restricted to cells of the Pit-1 lineage. Endocrinology. 2003;144(10):4626–36. doi: 10.1210/en.2003-0357.

55. Ahltainen P, Sharp V, Rulli SB, Rivero-Muller A, Mamaeva V, Roytta M, et al. Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocrinol Relat Cancer. 2010;17(3):611–21. doi: 10.1677/ERC-10-0016.

56. Gonzalez B, Ratner LD, Di Giorgio NP, Poutanen M, Huhtaniemi I, Allan CM, Kalak R, Dunstan CR, McTavish KJ, Zhou H, Iqbal J, Sun L, Zaidi M. Commentary-FSH and bone 2010: an overview of FSH action and role in bone. Rev Endocr Metab Disord. 2011;12:245–58. doi: 10.1007/s11154-010-9157-z.

57. Ilmela M, Poutanen M, Toppari J, Huhtaniemi I. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001;76(9):906–9. doi: 10.4065/76.9.906.

58. Haasl RJ, Ahmadi MR, Meethal SV, Gleason CE, Johnson SC, Asantha S, et al. A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer’s disease in males carrying an apolipoprotein E epsilon4 allele. BMC Med Genet. 2008;9:37. doi: 10.1186/1471-2350-9-37.

59. Bowman RL, Verdiel G, Liu T, Parlow AF, Perry G, Smith MA, et al. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem. 2004;279(19):20539–45. doi: 10.1074/jbc.M311993200.

60. Lin J, Li X, Yuan F, Lin L, Cook CL, Rao ChV, et al. Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol. 2010;69(3):253–61. doi: 10.1097/NEN.0b013e3181d072cf.

61. Tam J, Danilovich N, Nilsson K, Sairam MR, Maysinger D. Chronic estrogen deficiency leads to molecular aberrations related to neurodegenerative changes in follitropin receptor knockout female mice. Neuroscience. 2002;114(2):493–506. doi: S0306452202002786.

62. Zhang FP, Pakarainen T, Poutanen M, Toppari J, Huhtaniemi I. The low gonadotropin-independent constitutive production of testosterone is sufficient to maintain spermatogenesis. Proc Natl Acad Sci USA. 2003;100(23):13692–7. doi: 10.1073/pnas.2232815100.

63. d’Anglemont de Tassigny X, Fagg LA, Dixon JP, Day K, Leitch HG, Hendrick AG, et al. Hypogonadotropic hypogonadism in males carrying an apolipoprotein E epsilon4 allele. Proc Natl Acad Sci USA. 2003;100(23):13692–7. doi: 10.1073/pnas.2232815100.

64. Asthana S, et al. A luteinizing hormone receptor intronic variant is significantly associated with Alzheimer disease: potential neurodegenerative mechanisms. Endocrinol. 2006;29(2):257–69. doi: 10.1835/ENDO.29:2.257.

65. Leit ZM, Rao CV, Komyey JI, Licht P, Huat ES. Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain. Endocrinology. 1993;132(3):2262–70.

66. Kuorelahti A, Rulli S, Huhtaniemi I, Poutanen M. Human androgen receptor and promotes steroidogenesis in the adrenal cortex. J Clin Invest. 2000;105(5):633–41. doi: 10.1172/JCI7716.
85. Allan CM, Wang Y, Jimenez M, Marshan B, Spaliviero J, Illingworth P, et al. Follicle-stimulating hormone increases primordial follicle reserve in mature female hypogonadal mice. J Endocrinol. 2006;188(3):549–57. doi:10.1677/joe.1.06614.

86. Haywood M, Tymchenko N, Spaliviero J, Koch A, Jimenez M, Gromoll J, et al. An activated human follicle-stimulating hormone (FSH) receptor stimulates FSH-like activity in gonadotropin-deficient transgenic mice. Mol Endocrinol. 2002;16(11):2582–91.

87. Allan CM, Lim P, Robson M, Spaliviero J, Handelsman DJ. Transgenic mutant D567G but not wild-type human FSH receptor overexpression provides FSH-independent and promiscuous glycoprotein hormone Sertoli cell signaling. Am J Physiol Endocrinol Metab. 2009;296(5):E1022–8. doi:10.1152/ajpendo.90941.2008.